4-(2,6-dimethoxy-pyrimidin-4-ylamino)-piperidine-1-carboxylic acid tert-butyl ester | 1000207-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2,6-dimethoxy-pyrimidin-4-ylamino)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[(2,6-dimethoxypyrimidin-4-yl)amino]piperidine-1-carboxylate
• CAS: 1000207-42-0
• 化学式: C₁₆H₂₆N₄O₄
• 分子量: 338.407
• InChiKey: PUXNDBKOBZOIDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(2,6-dimethoxy-pyrimidin-4-ylamino)-piperidine-1-carboxylic acid tert-butyl ester 在 盐酸 、 乙醇 作用下， 以 1,4-二氧六环 为溶剂， 反应 48.0h， 生成 4-methoxy-6-(piperidin-4-ylamino)-pyrimidin-2-ol dihydrochloride
  参考文献：
  名称：

  WO2008/692

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氯-2,4-甲氧基嘧啶 、 1-Boc-4-氨基哌啶 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 、 乙腈 为溶剂， 反应 1.5h， 以33%的产率得到4-(2,6-dimethoxy-pyrimidin-4-ylamino)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2008/692

  摘要：

  公开号：

文献信息

• Pyrimidine and quinazoline derivatives
  申请人：Christ Andreas D.

  公开号：US20080045550A1

  公开（公告）日：2008-02-21

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物，其中A，R1到R5和G的定义如描述和权利要求中所述，并且其药学上可接受的盐。本发明还涉及含有这些化合物的制药组合物，以及其制备过程和用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Pyrimidine and Quinazoline Derivatives
  申请人：Christ Andreas D.

  公开号：US20100069413A1

  公开（公告）日：2010-03-18

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及公式中的化合物，其中A、R1至R5和G如描述和权利要求中所定义，并且其药学上可接受的盐。本发明还涉及含有这些化合物的药物组合物，以及制备它们的过程和它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Substituted piperidine derivatives as SST5 modulators
  申请人：Hoffmann-La Roche Inc.

  公开号：US07968568B2

  公开（公告）日：2011-06-28

  This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物，其中A，R1到R5和G的定义如说明书和权利要求所述，并且其药学上可接受的盐。本发明还涉及包含这些化合物的药物组合物，以及制备它们的过程和它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Pyrimidine and quinazoline derivatives as SST5 modulators
  申请人：Hoffmann-La Roche Inc.

  公开号：US07674804B2

  公开（公告）日：2010-03-09

  This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及式中的化合物，其中A，R1至R5和G如描述和权利要求中所定义，并且其药学上可接受的盐。本发明还涉及含有这种化合物的制药组合物，以及它们的制备方法和用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2044054A2

  公开（公告）日：2009-04-08